Enjoy these illustrated stories and learn more about key topics, practices and protocols.
Which anti-VEGF treatment regimen?
Intravitreal anti-vascular endothelial growth factor agents, such as aflibercept, ranibizumab, and bevacizumab, have revolutionised the way neovascular retinal diseases are managed. However, there are still questions about the most effective dosing schedule for these medications to help optimise treatment effect and patient experience. Here, Sebastian Wolf highlights the key differences between the most commonly used dosing schedule.
DRCR.net Protocol T study: 1- and 2-year results
Sanjay Sharma gives an overview of both the 1- and 2-year results from the DRCR.net Protocol T study comparing aflibercept, ranibizumab and bevacizumab.